Howland Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 0.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 136,283 shares of the medical research company’s stock after purchasing an additional 560 shares during the quarter. Thermo Fisher Scientific comprises about 2.1% of Howland Capital Management LLC’s investment portfolio, making the stock its 10th largest position. Howland Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $25,785,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the company. BlackRock Inc. grew its stake in Thermo Fisher Scientific by 2,692.1% in the 1st quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock valued at $3,531,095,000 after acquiring an additional 22,165,530 shares during the last quarter. Capital Research Global Investors grew its stake in Thermo Fisher Scientific by 29.8% in the 2nd quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock valued at $3,019,185,000 after acquiring an additional 3,973,136 shares during the last quarter. Janus Henderson Group PLC grew its stake in Thermo Fisher Scientific by 2,058.1% in the 2nd quarter. Janus Henderson Group PLC now owns 2,342,046 shares of the medical research company’s stock valued at $408,620,000 after acquiring an additional 2,233,522 shares during the last quarter. Veritas Asset Management LLP grew its stake in Thermo Fisher Scientific by 112.4% in the 2nd quarter. Veritas Asset Management LLP now owns 2,430,759 shares of the medical research company’s stock valued at $424,095,000 after acquiring an additional 1,286,259 shares during the last quarter. Finally, Harbour Capital Advisors LLC grew its stake in Thermo Fisher Scientific by 18,197.5% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,201,051 shares of the medical research company’s stock valued at $6,884,000 after acquiring an additional 1,194,487 shares during the last quarter. 85.32% of the stock is currently owned by institutional investors and hedge funds.

Shares of Thermo Fisher Scientific Inc (TMO) opened at $192.93 on Wednesday. The stock has a market cap of $76,590.12, a P/E ratio of 20.99, a P/E/G ratio of 1.75 and a beta of 1.08. Thermo Fisher Scientific Inc has a 1 year low of $139.07 and a 1 year high of $201.20. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.24 by $0.07. The firm had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The company’s revenue was up 13.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.03 EPS. analysts expect that Thermo Fisher Scientific Inc will post 9.36 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.19%.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/22/howland-capital-management-llc-buys-560-shares-of-thermo-fisher-scientific-inc-tmo.html.

TMO has been the topic of a number of recent research reports. Zacks Investment Research lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, July 31st. BidaskClub lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Argus restated a “buy” rating on shares of Thermo Fisher Scientific in a report on Tuesday, August 22nd. They noted that the move was a valuation call. Cowen and Company restated a “buy” rating and issued a $200.00 target price on shares of Thermo Fisher Scientific in a report on Friday, September 1st. Finally, Morgan Stanley restated an “overweight” rating and issued a $220.00 target price on shares of Thermo Fisher Scientific in a report on Wednesday, September 6th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Thermo Fisher Scientific has a consensus rating of “Buy” and an average target price of $205.71.

In related news, VP Peter E. Hornstra sold 3,894 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total transaction of $721,090.92. Following the completion of the sale, the vice president now owns 19,751 shares of the company’s stock, valued at approximately $3,657,490.18. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the sale, the chief executive officer now directly owns 252,577 shares of the company’s stock, valued at approximately $47,582,981.03. The disclosure for this sale can be found here. In the last three months, insiders have sold 60,420 shares of company stock valued at $11,308,477. Corporate insiders own 0.49% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.